{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-050433","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2024-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.458469+00:00","generated_at":"2026-05-29T02:41:14.640747+00:00","sec_items":["3.01","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AIM ImmunoTech receives NYSE American delisting notice for stockholders' equity deficit","bullets":["Stockholders' deficit of $2.9M as of Sept 30, 2024; fails $4M and $6M equity thresholds.","Must submit compliance plan by Jan 10, 2025; cure period until June 11, 2026.","Stock to trade with \".BC\" designation while below compliance; no immediate impact on listing.","Company has reported net losses in five most recent fiscal years.","If plan not accepted or compliance not regained, delisting proceedings may commence."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-050433","json":"https://secwatch.observer/filing/0001493152-24-050433.json","markdown":"https://secwatch.observer/filing/0001493152-24-050433.md","text":"https://secwatch.observer/filing/0001493152-24-050433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315224050433/0001493152-24-050433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315224050433/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:41:14.640747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b0f2cb4ecaad97aea4b4e2d30cd02a8d4a911b37","claim":"AIM ImmunoTech Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii), 1003(a)(iii)).","evidence_excerpt":"losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of September 30, 2024, the Company had a stockholders’ deficit of $2.9 million and has had losses in the most recent five fiscal years ended December 31, 2023. The Company is now subject to the procedures and requirements of Section 1009 of the Company","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315224050433/0001493152-24-050433-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nyse american"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"1003(a)(ii), 1003(a)(iii)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}